CWP232228
目录号 : KM12998 CAS No. : 1144044-02-9 纯度 : 98%

CWP232228 是一种高效的选择性 Wnt/β-catenin 信号通路抑制剂,在细胞核中,拮抗 β-catenin 与 T 细胞因子 (TCF) 结合。CWP232228 通过抑制乳腺癌和肝癌干细胞 (CSCs) 的生长来抑制肿瘤的形成和转移而无毒性。

规格 价格 是否有货 数量
5mg
In-stock
10mg
In-stock
50mg 询价 In-stock
100mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs).

IC50&Target

Wnt/β-catenin

体外研究

CWP232228 (0.01-100 μM; 48 hours) inhibits cell proliferation with IC50 values are 2 and 0.8 μM in mouse (4T1) and human (MDA-MB-435) breast cancer cell lines, respectively.
CWP232228 (0.01-10 μM; 48 hours) inhibits cell proliferation with IC50s of 2.566, 2.630, and 2.596 μM in Hep3B, Huh7 and HepG2 cells, respectively.

Cell Proliferation Assay

Cell Line: Mouse (4T1) and human (MDA-MB-435) breast cancer cell lines
Concentration: 0.01, 0.1, 1, 10, 100 μM
Incubation Time: 48 hours
Result: IC50s were 2 and 0.8 μM for 4T1 and MDA-MB-435 cell lines, respectively.

Cell Proliferation Assay

Cell Line: Hepatocellular carcinoma cell lines HepG2, Huh7, and Hep3B
Concentration: 0.01, 0.1, 0.5, 1, 5, 10 μM
Incubation Time: 48 hours
Result: IC50s were 2.566, 2.630, and 2.596 μM for Hep3B, Huh7 and HepG2 cells, respectively.
体内研究

CWP232228 (100 mg/kg, administered i.p.; daily; 21days for mice bearing 4T1 cell tumors; 60 days for mice bearing MDA-MB-435 cell tumors) results in a significant reduction in tumor volume.

Animal Model: 7-week-old female Balb/c and NOD/SCID mice bearing 4T1 or MDA-MB-435 cell tumors
Dosage: 100 mg/kg
Administration: Administered i.p.; daily; 21days for mice bearing 4T1 cell tumors, 60 days for mice bearing MDA-MB-435 cell tumors
Result: Treatment resulted in a significant reduction in tumor volume.
分子式
C33H34N7Na2O7P
分子量
717.62
CAS号
1144044-02-9
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 62.5 mg/mL (87.09 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.3935 mL 6.9675 mL 13.9350 mL
5 mM 0.2787 mL 1.3935 mL 2.7870 mL
10 mM 0.1393 mL 0.6967 mL 1.3935 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

科研文献
暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度 mg/ml;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。